Dry Powder Inhaler Composition for Direct IPF Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic pulmonary fibrosis (IPF) are limited by the lack of effective methods to halt progressive scarring in the lungs, with existing inhalers facing issues such as inconsistent dosing, high manufacturing costs, and patient compliance, while oral medications cause significant adverse effects.
Innovation Solution
A dry powder inhaler system delivering a pharmaceutical composition comprising kinase inhibitors like nintedanib or diketopiperazine particles directly to the lungs, reducing adverse effects and ensuring consistent dosing for effective treatment of IPF and other lung diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral medications are used to treat IPF, then therapeutic efficacy is achieved, but adverse effects increase
Solution Approach 1:
The patent uses the lungs as an intermediary organ for drug delivery. By administering medications through inhalation, the drug is delivered directly to the target organ (lungs) bypassing the gastrointestinal tract, thereby achieving therapeutic efficacy while minimizing gastrointestinal adverse effects such as nausea, diarrhea, and abdominal pain
2Manufacturing precision
If dry powder inhaler systems are used, then dosing consistency is improved, but device complexity increases
Solution Approach 1:
The inhaler system is divided into separate modular components: a reusable inhaler body and replaceable cartridges containing the dry powder medication. This segmentation allows the complex dosing mechanism to be pre-fabricated in the cartridge, ensuring dosing consistency while keeping the inhaler body simple and easy to use for patients
3Reliability
If lung transplant is performed, then treatment effectiveness is improved, but invasiveness increases
Solution Approach 1:
The patent replaces the mechanical surgical intervention of lung transplant with a non-invasive inhalation therapy. The dry powder medication is delivered directly to the lungs through breath-powered inhalation, providing therapeutic effectiveness without the need for surgical transplantation and avoiding associated risks such as rejection, infection, and long immunosuppression therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dry powder inhaler system provides rapid and effective delivery of active agents to the lungs, minimizing side effects and improving patient compliance, while maintaining therapeutic efficacy with reduced dosing frequency and improved manufacturing practicality.
Implementation Method 1
administering the active agent in a therapeutically effective dose of a pharmaceutical composition comprising the active agent by oral inhalation for rapid delivery and onset of action of the active agent being delivered to lung tissue and that the active agent reaches the alveoli and the systemic circulation in the lungs
Data Source
AI summary
A method, composition and kit for the treatment of interstitial lung disease, including fibrotic lung disease, are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be administered to a subject in need by oral inhalation. The composition comprises diketopiperazine particles and a kinase inhibitor for oral inhalation.